A Look At China Medical System Holdings (SEHK:867) Valuation After New AI Drug Partnership And Trial Approval

Simply Wall St

Sun, February 15, 2026 at 3:08 PM GMT+9 4 min read

In this article:

CHSYF

-31.06%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Why these new drug moves matter for China Medical System Holdings

China Medical System Holdings (SEHK:867) has been busy on two fronts, pairing with Insilico Medicine on AI-powered drug discovery projects and securing Chinese regulator approval to start human trials for its CMS-D017 capsule.

Together, these developments point to a company putting more emphasis on central nervous system, autoimmune and complement mediated kidney diseases, while adding fresh early stage assets to an already established commercial portfolio in China.

See our latest analysis for China Medical System Holdings.

At a share price of HK$15.13, China Medical System Holdings has a 30 day share price return of 6.93% and a year to date share price return of 15.41%. Its 1 year total shareholder return of 101.60% contrasts with more moderate 3 and 5 year total shareholder returns of 32.69% and 30.26%, suggesting recent momentum has been much stronger than its longer term record.

If AI driven drug development is on your radar after this news, it could be a good time to scan the wider opportunity set with our screener of 57 profitable AI stocks that aren’t just burning cash.

With China Medical System trading at HK$15.13, showing recent share price momentum, an intrinsic discount flag and a discount to analyst targets, investors may ask whether there is still potential upside or if the market is already pricing in future growth.

Price-to-Earnings of 19.6x: Is it justified?

On a P/E of 19.6x with a last close of HK$15.13, China Medical System looks more expensive than the Hong Kong pharmaceuticals sector on this single metric, but cheaper than a closer peer set and close to its estimated fair ratio.

The P/E ratio compares the current share price to earnings per share. In other words, it shows how much the market is willing to pay for each dollar of profit. For a pharmaceutical business with an established commercial portfolio and active R&D pipeline, investors often use P/E to weigh current profitability against expected earnings growth.

Here, the picture is mixed. The stock screens as expensive versus the wider Hong Kong pharmaceuticals industry average P/E of 13.3x, which suggests the market is paying a premium to that broader group. At the same time, it sits below the peer average P/E of 25.3x and close to an estimated fair P/E of 21.1x. This points to a level the market could move toward if earnings delivery lines up with expectations.

Story Continues  

Explore the SWS fair ratio for China Medical System Holdings

Result: Price-to-Earnings of 19.6x (ABOUT RIGHT)

However, risks remain, including potential setbacks in clinical trials and any change in analyst expectations that could challenge the current valuation narrative.

Find out about the key risks to this China Medical System Holdings narrative.

Another way to look at value

While the P/E of 19.6x makes China Medical System look close to its fair ratio of 21.1x, our DCF model presents a different perspective. At HK$15.13, the shares are flagged as trading about 55.6% below an estimated value of HK$34.06. This raises a simple question: which signal do you place more weight on?

Look into how the SWS DCF model arrives at its fair value.

867 Discounted Cash Flow as at Feb 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out China Medical System Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 229 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own China Medical System Holdings Narrative

If you see the numbers differently or prefer to test your own assumptions, you can build a personalised view of China Medical System in just a few minutes, starting with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding China Medical System Holdings.

Looking for more investment ideas?

If you are serious about upgrading your portfolio after looking at China Medical System, do not stop here; broaden your opportunity set while others stay on the sidelines.

Spot potential value plays early by checking companies our screener flags as screener containing 560 high quality undiscovered gems before they land on everyone else's radar.

Lock in steadier income streams by scanning for 435 dividend fortresses that could complement growth focused holdings.

Prioritise resilience by reviewing 319 resilient stocks with low risk scores that may help smooth out the bumps across your overall portfolio.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include 0867.HK.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info